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Abstract
Multidrug-resistant bacteria (MDR) are increasing rapidly and posing a global threat to 
mankind. Alternative strategies other than antibiotics have to be explored urgently. In 
this chapter, we review the current status of nonantibiotics strategies including antibody-
based therapy and vaccine development for targeting Gram-positive strains (methicillin-
resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium) and MDR 
Gram-negative strains (Acinetobacter baumannii and Pseudomonas aeruginosa). Biologics-
based clinical progress against these bacterial infections is updated.
Keywords: multidrug-resistant bacteria, MDR, MRSA, VRE, A. baumannii, P. aeruginosa, 
infection, biologics, antibody, vaccine
1. Introduction
Antibiotics treatment for bacterial infections has been extensively used for over half century. 
This is coupled with increasing reports of bacteria drug resistance to almost all available 
classes of antibiotics.
The antibiotics multidrug resistance (MDR) situation is particularly severe in clinics and 
community for the designated ESKAPE notorious bugs (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter 
spp.) [1, 2].
Given the prevalence of antibiotic resistance to these bacteria-associated infections, alternative 
strategies are urgently needed. This chapter reviews the current status of nonantibiotics-based 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
strategies including antibody-based therapy and vaccine development for Gram-positive strains 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium 
(VRE) and MDR Gram-negative strains (A. baumannii and P. aeruginosa). Figure 1 shows the basic 
Figure 1. Bacterial cell and detailed cell wall architecture. Gram-positive bacterial cell (A1), the detailed Gram-positive 
bacterial cell wall (A2), Gram-negative bacterial cell (B1) and the detailed Gram-negative bacterial cell wall (B2) are 
shown.
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Drug name Sponsor (s) Target Product class Indication Development 
stage
Ref.
Altastaph Nabi Biopharmaceuticals CP5/CP8 S. aureus 
antibody
Treatment of bacteremia and 
continuing fever
Phase I/II [48]
Aurexis 
(Tefibazumab)
Bristol-Myers Squibb ClfA S. aureus 
antibody
Treatment of bacteremia Phase II [68]
Aurograb NeuTec Pharma ABC transporter 
GrfA
S. aureus 
antibody
Treatment of severe, deep-seated 
infections
Phase III, failed [189]
Pagibaximab Biosynexus Inc./
GlaxoSmithKline
Lipoteichoic acid S. aureus 
antibody
Prevention of staphylococcal sepsis 
in very low birth weight infants
Phase II/III, failed [190]
MEDI4893 MedImmune LLC α-toxin S. aureus 
antibody
Prevention of pneumonia Phase II [36]
SAR279356 (F598) Sanofi PNAG S. aureus 
antibody
Prevention of pneumonia Phase II, 
terminated
[191]
Veronate Bristol-Myers Squibb ClfA and SdrG S. aureus 
antibody
Prevention of infections in neonates Phase III [192]
SA3Ag Pfizer CP5/CP8/ClfA S. aureus vaccine Prevention of infections Phase I/II [92]
StaphVAX Nabi Biopharmaceuticals CP5/CP8 S. aureus vaccine Prevention of infections Phase III, failed [50]
STEBVax National Institute of Allergy 
and Infectious Diseases
SEB S. aureus vaccine Treatment for toxic shock syndrome Phase I [193]
V710 Merck IsdB S. aureus vaccine Prevention of infections Phase III, failed [194]
SA4Ag Pfizer CP5/CP8/ClfA/ 
MntC
S. aureus vaccine Prevention of infections Phase I, II, IIb [195]
4C–Staph GSK HlaH35L/EsxAB/
FhuD2/Csa1A
S. aureus vaccine Prevention of infections Phase I [196]
MEDI3902 MedImmune LLC PcrV/Psl P. aeruginosa 
antibody
Prevention of pneumonia Phase II [197]
KB001-A KaloBios Pharmaceuticals PcrV P. aeruginosa 
antibody
Prevention of infections Phase II, failed [198]
Physiology and Pathology of Multidrug-Resistant Bacteria: Antibodies- and Vaccines-Based...
http://dx.doi.org/10.5772/intechopen.70488
201
Drug name Sponsor (s) Target Product class Indication Development 
stage
Ref.
PseudIgY Immunsystem AB Unknown P. aeruginosa 
antibody
Prevention of infections Phase I/II [199]
KBPA-101 Kenta Biotech Ltd O-polysaccharide P. aeruginosa 
antibody
Treatment of infections Phase I/II [200]
IC43 Valneva Austria GmbH OprF/OprI P. aeruginosa 
vaccine
Prevention of infections Phase II/III [201]
Aerugen Crucell O-polysaccharide P. aeruginosa 
vaccine
Prevention of chronic CF infection Phase III, failed [140]
Flagella Subtype-a and 
subtype-b flagellin
P. aeruginosa 
vaccine
Prevention of chronic CF infection phase III [131]
MEP Univax Biologics MEP antigen P. aeruginosa 
vaccine
Prevention of chronic CF infection Phase I [142]
Pseudostat Provalis PLC Inactivated P. 
aeruginosa strain 385
P. aeruginosa 
vaccine
Prevention of chronic CF infection Phase I [145]
CP5/8: serotype 5/8 capsular polysaccharides; ClfA: clumping factor A; PNAG: poly-N-acetyl glucosamine; SdrG: serine-aspartate repeat-containing protein G; SEB: 
Staphylococcal enterotoxin serotype B; IsdB: iron-regulated surface determinant protein B; MntC: manganese transport protein C; HlaH35L: α-Hemolysin H35L; EsxAB: 
ess extracellular A/B; FhuD2: ferric hydroxamate-binding lipoprotein; Csa1A: conserved staphylococcal antigen 1A; PcrV: Low calcium response locus protein V; OprF/
OprI: Major outer membrane porin F/I; MEP: mucoid exopolysaccharide.
Table 1. Antibodies and vaccines for S. aureus and P. aeruginosa in clinical development.
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structures of Gram-positive and Gram-negative bacteria that are a key for design and develop-
ment of antibodies and vaccines to target against these MDR bacterial infections.
Monoclonal antibodies (mAbs) have advantages over traditional chemotherapy in that 
(1) mAbs can bind target antigen specifically and thus reduce off-target side effects asso-
ciated with traditional chemotherapy; (2) through Fc neonatal receptor (FcRn) recycling 
mechanism, mAbs have long serum half-life (ranges in days to weeks) when compared to 
chemotherapy (ranges in minutes to hours); (3) mAbs can recruit effectors for antibody-
dependent cell-mediated phagocytosis (ADCP), antibody-dependent cellular cytotoxic-
ity (ADCC), and complement-dependent cytotoxicity (CDC) through its Fc region, which 
functions are missing in chemotherapy [3]. By 2015, more than 60 monoclonal antibodies 
(mAbs) have been approved by the United States Food and Drug Administration to treat 
cancer, autoimmune disorders, and infections [4].
To conquer the serious antibiotic resistance from bacterial pathogens, passive immunization 
(mAb treatment against bacterial pathogen) and active immunization (vaccine against bacte-
rial pathogen), as alternative strategies, are being actively explored.
In this chapter, we focus on the current status of antibody and vaccine development against 
Gram-positive strains (S. aureus and Enterococci) and Gram-negative strains (P. aeruginosa and 
A. baumannii). Antibodies and vaccines under clinical trials are summarized in Table 1.
2. Antibody and vaccine development against S. aureus
S. aureus establishes infection through a variety of complicated mechanisms. S. aureus pro-
duces cell envelope-associated proteins, nonprotein glycopolymers, a collection of secreted 
toxins that mediate host-microbe adhesion, host cell lysis, antibody function interference, 
complement activation inhibition, and invasion of immune nonprofessional phagocytes [5, 6].
2.1. Antibodies against staphylococcal-secreted virulent factors
2.1.1. Staphylococcal superantigens as antibody targets
S. aureus is a round-shaped, facultative anaerobe, which can produce an array of superantigens 
(SAgs), including staphylococcal exotoxins, enterotoxins, and toxic shock syndrome toxin 1 
(TSST-1). These toxins exert their hyper-stimulatory properties and cause food poisoning, toxic 
shock syndrome, acute lung diseases, and autoimmune diseases [7–10]. The superantigenicity 
of SAgs is largely achieved by the activation of APCs and T cells, leading to a massive release 
of cytokines, including IL-1β, IL-6, and TNFα [11].
Staphylococcal enterotoxin serotype B (SEB) was classified as a category B select agent by the 
Centers for Disease Control and Prevention (CDC) due to its high toxicity to human and poten-
tial use as a biological weapon [12]. Several mAbs targeting on SEB are under investigation. A 
high-affinity SEB-specific mouse mAb, 20B1, was investigated in mouse models with superfi-
cial skin, sepsis, or deep-tissue infections [13]. Treatment of 20B1 significantly increased the 
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survival in the sepsis model, whereas it reduced bacterial burden and dissemination of bacteria 
in the superficial skin model. Moreover, 20B1 was shown to decrease pro-inflammatory cyto-
kine levels and T cell proliferation. Remarkably, their following work further showed that iso-
type switching from original IgG1 to IgG2a, without changing of SEB binding affinity, greatly 
enhanced the protective ability in S. aureus sepsis models [14]. This is consistent with a recent 
report in which humanized anti-SEB mAbs attenuated virulence of exogenous SEB expressing 
S. aureus in a mouse pneumonia model [15].
In addition, Tilahun and colleagues explored the use of combined mAbs targeting on dif-
ferent epitopes of SEB, as well as co-administration of mAb and antibiotic, both of which 
showed synergistic protection in S. aureus infection mouse model [16, 17]. This strategy seems 
promising as synergistic protection by co-administration of two mAbs recognizing distinct 
SEB epitopes was also observed independently in another study [18]. To date, there are not 
any anti-SEB mAbs being tested in clinical trials. Of note, a phase I clinical study of safety of 
a recombinant SEB vaccine (STEBVax) against toxic shock syndrome has been completed [19].
TSST-1 is a 22 kDa monomeric protein, of which the N-terminal domain binds to the MHC-II 
on APCs and the C-terminal domain is implicated in β-chain variable region of TCR (TCR-Vβ) 
interaction [20, 21]. In a recent report, human single chain variable fragments (scFvs) against 
recombinant TSST-1 were panned out from synthetic human scFv library by phage display 
technology [22]. The scFvs were demonstrated to be able to inhibit TSST-1–mediated T cell 
activation and pro-inflammatory cytokine production. Besides, a recombinant TSST-1 vaccine 
(Biomedizinische Forschungs gmbH) has been completed in phase I clinical study and proved 
to possess a good safety profile with no observable severe adverse events occurred [23, 24].
2.1.2. α-Hemolysin as antibody target
S. aureus releases a number of cytolytic toxins, among which the pore-forming α-hemolysin 
(Hla, α-toxin) is the most studied one. Hla is secreted as a 33 kDa monomer consisting almost 
entirely of β-strands by circular dichroism [25]. It exerts cell lytic activity through a mem-
brane perforating mechanism, which is initiated through binding to membrane lipid or/and 
its proteinaceous receptor, a disintegrin and metalloprotease 10 (ADAM10) [26]. In detail, Hla 
monomers assemble into a heptameric structure on susceptible host cell membrane and form 
a central pore of approximately 1–3 nm in diameter [27, 28]. This allows rapid egress of Ca+, 
ATP, and low molecular weight molecules through the pore, resulting in alteration of cellular 
signaling pathways and cell lysis [29–31].
Therapeutic anti-Hla mAbs have been actively developed due to the key role of Hla in 
Staphylococcal pathogenesis. In a study in which a recombinant Hla, AT62, was used as a vaccine, 
the study also showed that passive immunization of anti-AT62 IgG reduced wound infection and 
tissue damage in a mouse model [32]. In a S. aureus dermonecrosis model, combined administra-
tion of Hla-targeting mAb, MEDI4893*, with frontline antibiotic linezolid or vancomycin, exhibited 
enhanced protection by reduced lesion size, reduced tissue damage, and accelerated healing in a 
synergistic manner [33]. Furthermore, MEDI4893 (MedImmune) was generated from MEDI4893* 
by introducing three amino acids substitution (M252Y/S254 T/T256E) [33]. The YTE mutation 
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has been shown to extend half-life by two- to fourfold without affecting distribution properties 
[34]. MEDI4893 not only abrogated Hla-host cell interaction but also potentially blocked oligo-
mer formation due to steric hindrance [35]. Recently, a phase I clinical trial was completed by 
evaluating the safety, tolerability, and pharmacokinetics of MEDI4893 in healthy adult subjects 
[36]. Currently, a phase II study is ongoing to evaluate the safety and efficacy of MEDI4893 in the 
prevention of S. aureus pneumonia [37].
2.2. Antibodies against staphylococcal surface-associated components
2.2.1. Capsular glycopolymer as antibody target
Bacterial capsule is a polysaccharide layer lying outside of the cell wall found in both Gram-
positive and Gram-negative bacteria. Capsule produced by pathogens has been involved in 
promoting adherence, resisting bacterium from host immune attack, and mediating release of 
virulent factors [38]. Encapsulation of S. aureus prevents bacterial phagocytosis by interfering 
with effective opsonization [39].
Serotype 5 (CP5) and serotype 8 (CP8) capsular polysaccharides predominate among S. aureus 
clinical isolates, representing 75–80% of total isolates [40]. While several CP5 or CP8-specific 
mAbs were studied [41, 42], serum containing antibodies that recognize the shared epitope of 
CP5 and CP8 were recently developed [43, 44]. The cross-reactivity was confirmed in vitro and 
the sera were demonstrated to promote opsonophagocytic killing of both CP5 and CP8 S. aureus 
strains. There are no reports on therapeutic antibodies targeting staphylococcal polysaccharide 
in clinical trials. However, two vaccines, StaphVAX and Altastaph (Nabi Biopharmaceuticals), 
have been completed for their clinical studies for safety and immunogenicity evaluation [45–48]. 
Although Altastaph was able to induce significant elevation of anti-CP5 and anti-CP8 antibody 
levels, unfortunately, it failed to show efficacy in a phase II clinical trial [49]. StaphVAX also 
showed ineffectiveness in the reduction of S. aureus in patients on hemodialysis and thus failed 
in a phase III trial [50].
Bacterial poly-N-acetyl glucosamine (PNAG) is another major class of surface polysaccharide 
that has been evaluated as a vaccine. PNAG, which is synthesized by enzymes encoded in 
intercellular adhesin (ica) locus, contributes to biofilm formation, colonization in host tissue, 
and immune evasion [51, 52]. Recent work showed that deacetylation of PNAG (dPNAG) by 
surface protein, IcaB, is a critical step for PNAG association to cell wall and plays key roles 
in colonization and resistance to host immune defense [53]. Indeed, antibodies specific to 
dPNAG were better in opsonic killing than that specific to PNAG [54]. In consistence, passive 
immunization of mice with antisera raised to dPNAG showed efficient clearance of S. aureus, 
compared with that raised to acetylated form [55].
2.2.2. Staphylococcal protein A as antibody target
Staphylococcal protein A (SpA) is anchored to S. aureus cell wall by sortase A through amide 
linking of its C-terminal threonine of LPXTG motif to pentaglycyl crossbridge within pepti-
doglycan [56]. SpA interferes with immunoglobulin (Ig) function by binding to Fcγ domain 
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of Ig and prevents the bacterium from opsonophagocytic killing [57]. It also interacts with B 
cell receptor through binding with VH3-clan of antigen-binding fragment (Fab) region and 
induces supraclonal B cell responses, resulting in insufficient adaptive responses against 
infection [58–60].
Based on the mechanistic studies, a mutated form of SpA, SpA(KKAA), was generated to 
abolish both Fcγ and Fab binding abilities [61]. Vaccination of SpA(KKAA) was able to elicit 
robust antibody responses against multiple staphylococcal antigens in a MRSA-infection 
mouse model. In their following studies, passive immunization of antibodies specific for 
SpA(KKAA) significantly promoted opsonophagocytic clearance, reduced abscess formation, 
and decreased the mortality [62]. Furthermore, a humanized version successfully conferred 
protection against S. aureus sepsis in neonatal mice [63].
2.2.3. Clumping factor A as antibody target
Microbial adhesion to host tissue is crucial to infection initiation in most of the bacterial infec-
tions. Microbial surface component recognizing adhesive matrix molecules (MSCRAMM), 
such like clumping factor A (ClfA), plays a vital role in this process [64]. ClfA, a fibrinogen-
binding protein, is required for establishing early infection, abscess formation, protection 
against phagocytosis, as well as bacterial persistence in host [65, 66].
Tefibazumab, a humanized anti-ClfA mAb, was developed and exhibited high affinity and 
specificity for ClfA [67]. In vitro study showed that tefibazumab inhibited fibrinogen-binding 
ability of ClfA and protected against MRSA infection in murine septicemia and rabbit infec-
tive endocarditis models. Safety and pharmacokinetic profile of tefibazumab were evaluated 
in phase II clinical trial [68]. Unfortunately, it failed to show significant differences between 
treatment and placebo groups in overall adverse clinical events. A detailed analysis of ClfA-
fibrinogen structure observed a modest IC50 value of binding between ClfA and tefibazumab, 
which might partly explain the unsatisfactory clinical outcome [69].
2.2.4. Autolysin as antibody target
Autolysin (Atl) is a cell wall-associated enzyme with various functions. The major S. aureus 
autolysin (AtlS) contains two distinct domains, amidase and glucosaminidase, which are 
responsible for enzyme localization to cell wall and peptidoglycan hydrolysis, respectively 
[70, 71]. Atl participates in biofilm formation, separation of daughter cells after cell division 
and attachment to host matrix [72]. Moreover, AtlS is highly conserved among strains of 
S. aureus and other Staphylococci. These features together make AtlS an attractive target for 
anti-S. aureus mAb and vaccine investigation.
To test it, a mAb, 1C11, was generated to inhibit AtlS glucosaminidase domain and its effect in 
animal model was assessed [73, 74]. The mAb was shown to impair cell growth and cause cell 
aggregation and sedimentation in in vitro assay. Following this study, administration of 1C11 
reduced severity of implant-associated osteomyelitis in a mouse model by decreased abscess 
numbers and efficient internalization of antibody-opsonized S. aureus.
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Immunodominant staphylococcal antigen A (IsaA) is another highly conserved Atl. Similarly, 
protection was conferred by a mAb specific to IsaA in a mouse model [75]. The mode of action 
of mAb is mainly through activation of professional phagocytes and induction of oxidative 
burst activity of neutrophil.
2.3. Antibodies against staphylococcal cell wall components
2.3.1. Lipoteichoic acids as antibody target
Most Gram-positive bacteria produce teichoic acids (TAs) to facilitate their survival under dis-
advantageous conditions. Teichoic acids covalently link to either peptidoglycan or cytoplas-
mic membrane, known as wall teichoic acids (WTA) and lipoteichoic acids (LTA), respectively 
[76]. The roles of TAs in pathogenic bacteria include adherence to host cells [77], activation of 
complement [78], and cytokine induction [79].
Since structures of LTA are highly conserved across many clinical isolates, including 
Enterococci, Staphylococci, and several Streptococci, LTA is considered as a promising target 
for vaccine and therapeutic antibody development [80]. In a recent report, antibodies against 
E. faecalis LTA were used to test cross-activity with other Gram-positive bacteria, including 
S. aureus [80]. The in vitro data showed that the antibodies were also able to bind with LTA 
purified from S. aureus. Remarkably, the antibodies exhibited 60–90% opsonophagocytic 
killing activity across a variety of S. aureus strains, and great protection against MRSA infec-
tion in a mouse peritonitis model. In accordance with the observation, immunization with 
a BSA-conjugated LTA fragment, containing a conserved minimal structure in majority of 
Gram-positive bacteria, was able to induce opsonic killing of E. faecium E1162 and S. aureus 
MW2 [81]. Besides, immunization of WTA also elicited an anti-WTA immune response, 
illustrated by complement-dependent opsonophagocytosis [82, 83].
2.3.2. Peptidoglycan as antibody target
Peptidoglycan (PG) is composed of cross-linked polysaccharide and peptide chains, which 
forms the backbone of bacterial cell wall. So far, reports on therapeutic antibody or vaccine 
targeting on PG are scarce. A mAb against deacetylated peptidoglycan, ZBIA5H, was screened 
with best protective property in mouse models [84]. Surprisingly, ZBIA5H did not show the 
highest affinity to PG, compared with other mAbs. The superior property of ZBIA5H may 
be attributed to the unique epitope it recognizes. This study highlights that besides antigen 
binding affinity, other factors, such as epitope, should also be taken into consideration in 
therapeutic antibody discovery.
2.4. Antibodies against nutrient transporter proteins
Nutrient acquisition is one of the most basic and essential process virtually in all forms of life. 
Vertebrate host has evolved powerful strategy, termed nutritional immunity, to limit prolif-
eration of invading pathogens by sequestering essential nutrients [85]. One of the best char-
acterized examples of nutritional immunity is transition-metal-ion sequestration in which 
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metal ions are predominantly trapped by host metal-binding proteins [86]. To combat with 
host defensive system, microorganism employs mechanisms to maintain intracellular metal 
homeostasis. Therefore, these mechanisms could be suitable targets for therapeutic antibody 
development. For example, an Fab was screened to inhibit acquisition pathway for Mn(II), 
which is essential for detoxification of reactive oxygen species (ROS) [87, 88]. The mAb is 
bound to manganese transporter C (MntC) of an ATP-binding cassette (ABC) transporter sys-
tem and thereby blocks the metal delivery to the channel. In vitro assay showed that the Fab 
increased the sensitivity of S. aureus to ROS by over 10-fold.
An earlier report identified ABC transporter as the most commonly associated protein with 
IgG from the sera of 26 patients suffered with septicemia [89]. ScFvs against the conserved 
peptides from the ABC transporter were then panned from a phage display library and were 
shown to reduce the bacterial burden in a mouse model.
2.5. Multicomponent vaccines
So far, neither passive nor active immunization has shown potent efficacy on humans. The failure 
from basic research to clinical practice could partly be attributed to the limited understanding 
of the sophisticated events associated with every stage of infection. Prior strategies targeting on 
single virulent factor showed efficacy only in certain experimental settings. In this regard, novel 
vaccine formulations targeting on multiple pathogenic components are proposed to offer protec-
tion from distinct aspects through a synergistic working mode.
Recently, efficacy of a combination vaccine, 4C–Staph (four-component S. aureus vaccine), 
was evaluated [90]. 4C–Staph is composed of detoxified α-Hemolysin, a fusion of ess extracel-
lular A (EsxA) and ess extracellular B (EsxB), two staphylococcal surface proteins, which are 
ferric hydroxamate-binding lipoprotein (FhuD2) and conserved staphylococcal antigen 1A 
(Csa1A). 4C–Staph induced broad and synergistic protection against several Staphylococcal 
clinical isolates in different models. In addition, mechanistic study showed that the protection 
was mainly antibody dependent.
SA3Ag (Pfizer), a tri-component vaccine, consists of CP5 and CP8 individually linked with 
a nontoxic form of diphtheria toxin, and a recombinant mutant form of clumping factor A 
(rClfAm) [91]. A phase I clinical trial was completed to evaluate safety, tolerability, and effect 
of SA3Ag [92]. This vaccine showed a relatively safe profile among older and young adults.
In order to further enhance protection against S. aureus, another component, MntC, was added 
to SA3Ag to form a four-component vaccine SA4Ag (Pfizer) [93]. In phase 1/2 clinical trials, sin-
gle-dose administration of SA4Ag was well-tolerated among young and older adults, shown by 
mild or moderate local reactions and comparable systemic events with placebo control [94, 95]. 
More excitingly, SA4Ag induced a rapid, robust, and sustained functional antibody response.
2.6. Antibody-antibiotic conjugate
While S. aureus has classically been considered as an extracellular pathogen, a growing body 
of evidence reveals that it is capable to survive and persist within host cells, including phago-
cytic cells, which are responsible for bacterial clearance [96, 97]. Although phagocytic cells, 
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particularly neutrophils and macrophages, can efficiently kill majority of invading bacteria, a 
small population of persisters can however turn the circulating phagocytes to “Trojan horses” 
to facilitate bacterial dissemination via bloodstream [98]. Meanwhile, intracellular persistence 
allows bacteria to escape from antibiotic and immune attack. Indeed, most of the current anti-
biotics are less efficient in intracellular S. aureus killing, which may partly explain the poor 
response to treatment and the high frequency of recurrence in clinical practice [99, 100].
Based on these findings, therapies specifically targeting on intracellular pathogen may pro-
mote clinical outcome. Similar to antibody-drug conjugate (ADC), which has been successfully 
applied for cancer therapy, antibody-antibiotic conjugate (AAC) was first proposed and evalu-
ated by Lehar and his colleagues in 2015 [101]. The AAC is composed of three building blocks: an 
antibody to target on bacteria, a highly bactericidal antibiotic payload, and a linker to attach anti-
biotic payload to the antibody. The AAC was designed with no antibacterial activity as antibiotic 
serves as a prodrug when covalently linked. However, when planktonic AAC-tagged bacteria 
are internalized by host cells, the antibiotics can be efficiently released in their active form by 
cleavage from host protease. Thus, the AACs take bacteria as “Trojan horses” to deliver potent 
antibiotics to cytoplasmic compartment and resulting in intracellular antibacterial effect. To 
their anticipation, the AAC was shown to efficiently restrict intracellular S. aureus growth when 
treatment was initiated several hours after intravenous infection. In contrast, poor efficacy was 
observed by delayed treatment of vancomycin. This result is particularly interesting as majority 
of bacteria were found to associate with neutrophils within 10–15 minutes [97]. Moreover, the 
AAC was able to limit metastasis of S. aureus to brain in an intravenous infection model.
3. Antibody and vaccine development against E. faecium
Different from S. aureus, which produces an array of virulent factors, pathogenesis of 
Enterococci is largely determined by their adherence to host tissue mediated by surface adhe-
sion components. Several most-studied components include aggregation substance proteins, 
collagen adhesins, enterococcal leucine-rich repeat-containing proteins, pili, polysaccharides, 
and glycolipid [102], which are potential targets for antibody and vaccine development.
3.1. Enterococcal pili as antibody target
Enterococcal surface pili are filamentous proteins with Ig-like folds and LPXTG motifs, 
which have been implicated in biofilm formation, endocarditis, and catheter-associated 
urinary tract infections (CAUTIs) [103, 104]. Endocarditis and biofilm-associated pilus A 
(EbpA), one of the most-studied pili in Enterococci, is widely present among Enterococcal 
species and highly conserved in N-terminal domains [105]. In detail, N-terminal domain 
of EbpA (EbpANTD) binds to host fibrinogen deposited on urinary catheter to facilitate 
Enterococcal colonization [106]. Sera against EbpANTD was recently shown to provide 
universal protection in a murine model by reducing bacterial titers of a broad spectrum of 
Enterococcal isolates, including E. faecalis, E. faecium, and VRE [105]. Consistently, vaccina-
tion of EbpA or EbpANTD, but not its carboxyl-terminal domain, diminished biofilm forma-
tion and prevented CAUTIs in E. faecalis infection model [106].
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3.2. Polysaccharide antigens as antibody targets
Based on a previous serotyping analysis, about 60% of E. faecalis isolates fall into four sero-
types from CPS-A to CPS-D [107]. CPS-C and CPS-D can express capsular polysaccharide, 
whereas CPS-A and CPS-B are nonencapsulated due to deficiency of essential gene locus 
[108]. In an early study, antibodies raised against LTA from CPS-A strain only opsonized 
acapsular CPS-A and CPS-B strains, but not encapsulated ones [109, 110]. To develop antibod-
ies against capsule-bearing CPS-C and CPS-D strains, a novel diheteroglycan was identified 
from capsular polysaccharide [110]. As a result, passive immunization of anti-diheterogly-
can antibodies successfully protected CPS-C and CPS-D E. faecalis bacteremia mouse model. 
However, it was observed that considerably lower susceptibility of CPS-C and CPS-D strains 
to opsonic killing by naturally acquired antibodies was present in healthy human sera as 
compared with CPS-A and CPS-B [111]. Therefore, capsule may be a natural barrier to access 
therapeutic antibody by masking antigens underneath.
3.3. Lipoproteins as antibody targets
A transcriptomic analysis from an E. faecalis infection mouse model identified two ABC 
transporter substrate-binding lipoproteins upregulated upon infection: PsaAfm for manga-
nese transport and AdcAfm for zinc transport [112]. Treatment of antibodies raised from 
recombinant proteins showed increased opsonic killing in vitro and reduced colony counts 
in a mouse bacteremia model. Protective role was also seen in treatment with antibodies 
against distinct ABC transporter proteins [113], suggesting the potential of ABC transporter 
as a therapy target in enterococcal infection.
4. Antibodies and vaccines against P. aeruginosa
Effective control of P. aeruginosa infections remains a challenging problem due to its remark-
able ability to evolve resistance to many antibiotics. Antibodies and vaccines are considered to 
be a promising and alternative strategy to treat or prevent P. aeruginosa infections in susceptible 
populations. The identified P. aeruginosa antibody and vaccine targets include the lipopolysac-
charide (LPS) O-antigens, pilus, flagella, alginate, outer membrane proteins (OMPs), mucoid 
exopolysaccharide (MEP), and antigens from the type III secretion system (T3SS) [114].
4.1. Antibody and vaccine development against T3SS translocation protein PcrV
Type III secretion system (T3SS), as a key virulence determinant in P. aeruginosa, is encoded 
by at least 42 genes and assembled as a needle-like apparatus that can directly inject bacte-
rial effector proteins into host cell to elicit pathological response [115]. PcrV is located at the 
tip of needle-like apparatus and closely involved in translocation of effector proteins from 
P. aeruginosa to host cell [115].
Fab 1A8, a human Fab antibody fragment, can specifically target against P. aeruginosa PcrV 
antigen and elicit protective effects for mice with lethal pulmonary P. aeruginosa challenge 
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[116]. KB001, a PEGylated anti-PcrV Fab fragment in clinical phase-2a trial for ventilator asso-
ciated and P. aeruginosa colonized but not for infected patients in intensive care units (ICUs), 
showed good safety, tolerability, and pharmacokinetic profile. Although statistical signifi-
cance was not observed for patients with KB001 treatment and placebo treatment, incidence 
of P. aeruginosa pneumonia was decreased in KB001 treatment group (31%) as compared to 
that of placebo treatment group (60%) [117]. Identification of anti-PcrV IgG from human sera 
confirms that PcrV is a vaccine target [118]. Moreover, human high titer anti-PcrV sera clearly 
have prophylactic effect for mice with lung P. aeruginosa infection [118].
4.2. Antibody and vaccine development against PsI
By construction and phenotypic screening of human scFv phage display libraries from periph-
eral blood B cells of healthy individuals and patients recovered from recent P. aeruginosa 
infections, mAbs against one epitope of Psl, the exopolysaccharide important for P. aeruginosa 
attachment to host cell and biofilm maintenance, was identified to show potent protection in 
several animal P. aeruginosa infection models [119]. Also, this finding suggests that PsI can 
be used as a vaccine target. However, most patients suffered from P. aeruginosa bloodstream 
infection (BSI) had low anti-PsI titer that showed nonprotective to P. aeruginosa BSI infection 
[120]. MEDI3902, the combination of anti-PsI and anti-PcrV in a bispecific format, showed 
synergistic protection against P. aeruginosa murine pneumonia models as compared with each 
parental mAb [121]. Moreover, MEDI3902 can synergize several classes of antibiotics for the 
treatment of clinical antibiotics resistant isolates [121].
4.3. Antibody and vaccine development against outer membrane proteins (OMPs)
OMPs form porins and other structural and functional components on the bacterial cell sur-
face. CFC-101, a mixture of OMPs from P. aeruginosa, was used to immunize healthy human 
volunteers in a phase I/IIa clinical trial [122]. CFC-101 was safe and immunogenic in eliciting 
human mAbs after immunization that can passively protect mice from lethal P. aeruginosa 
challenge [122].
OprF and OprI are the major OMPs that are surface-exposed and conserved in wild-type 
strains of P. aeruginosa [123]. In phase I human trials, OprF-OprI vaccine (IC43) conjugating 
with aluminum hydroxide was safe and induced specific antibodies in healthy volunteers 
and burn patients by intramuscular administration [124, 125]. Intranasal immunization of 
OprF-OprI vaccine followed by systemic boost elicited a long-lasting systemic and local lung 
mucosal antibody response in patients with chronic pulmonary diseases [126]. Recently, 
phase II study on ICU P. aeruginosa infection showed that IC43 also produced a significant 
immunogenic effect without mortality or safety concerns [127].
4.4. Antibody and vaccine development against flagellins and pilins
Flagella are essential for motility, chemotaxis, invasiveness, and adhesion of P. aeruginosa to 
activate host inflammatory responses [128]. Flagellin is the primary protein component of 
flagella and consists of subtype a and subtype b [129].
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A monovalent P. aeruginosa flagella vaccine was safe and immunogenic in healthy human 
adults by intramuscular immunization and showed high and long-lasting serum antibody 
(IgG and IgA) titers against flagella positive P. aeruginosa [130].
Then, a bivalent flagella vaccine, containing some of the flagella subtype antigens (a0a1a2 and 
b), was evaluated over a 2-year period on cystic fibrosis (CF) patients not colonized with P. aeru-
ginosa in phase III trial. The vaccine lowered the risk of patients for initial infection as compared 
with that from the placebo group, though not statistically significant. Therefore, multivalent 
vaccine against P. aeruginosa flagella subtypes a and b is needed to improve overall efficacy 
of vaccine to more flagella subtypes [131]. A multivalent protein fusion vaccine consisting of 
flagellin subtype a and b, Oprl and OprF epitope 8, was used to immunize mice that induced 
specific IgGs against each individual antigen [132]. Although these IgGs elicited potent ADCC 
and increased clearance of nonmucoid P. aeruginosa, which reflect the initial colonization of 
P. aeruginosa, they were less effective for mucoid P. aeruginosa, which represent the colonized 
and chronic P. aeruginosa biofilm formation [132]. Conjugation vaccine of flagellin subtype a 
(FLA) with polymannuronic acid (PMA) built from mannuronic acid, the major component of 
alginate and biofilm, induced protection against mucoid P. aeruginosa in mice and rabbits [133].
Pili, as one key virulent factor, are filaments of pilin polymers located at the pole of 
P. aeruginosa and are responsible for adhesion of P. aeruginosa to host epithelial surfaces and 
twitching motility [134, 135]. A disulfide loop (DSL) at the C-terminal of pilin is the major 
epitope in bridging adherence of P. aeruginosa to host cell [134, 135]. Single copy of DSL 
was not an effective immunogen in mice, whereas multi-copy of DSL peptides increased 
IgG response 1000 times [136]. Immunization of mice with full length pilin of P. aeruginosa 
induced mAbs that inhibited pili-mediated epithelial cell adhesion [137].
4.5. Antibody and vaccine development against LPS
LPS is the major component of the outer membrane of P. aeruginosa. LPS has two types, 
smooth or S-type and rough or R-type. S-type LPS consists of O-polysaccharide (O-antigen) 
repeats linked with a core-conserved oligosaccharide and a lipid A moiety, while R-type LPS 
lacks O-antigen and only contains the core oligosaccharide [138]. The S-type LPS is involved 
in nonmucoid and in early stage of P. aeruginosa infection in CF patients, whereas the R-type 
LPS is associated with mucoid and late stage of P. aeruginosa infection in CF patients [139]. 
The O-antigen is immunogenic in the host for the induction of protective antibodies, whereas 
lipid A is the core endotoxic component for induction of inflammatory responses [138]. More 
than 20 serotypes of O-antigens have been identified [138].
Pseudogen, a heptavalent O-antigen vaccine, showed efficacy in nonrandomized trials among 
adult cancer and burn patients in preventing fatal P. aeruginosa infections but no benefit in leu-
kemia and CF patients [139]. Furthermore, Aerugen, an octavalent vaccine, was developed by 
conjugating purified O-antigens from eight P. aeruginosa strains with exotoxin A. This vaccine 
induced high levels of specific opsonizing antibodies in CF patients and significantly reduced the 
frequency of chronic infection for 10 years without apparent adverse effects in a nonblind trial. 
However, a subsequent double blind, randomized, placebo-controlled phase III trial failed to con-
firm the initial positive results and the further development of this vaccine was suspended [140].
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4.6. Antibody and vaccine development against alginate
Alginate or mucoid exopolysaccharide (MEP), a linear polymer of partially acetylated 
D-mannuronic acid and L-guluronic acid, is the major component of the P. aeruginosa biofilm 
matrix and thus critical in persistence of the bacteria in the CF lung [141]. MEP is relatively 
conserved between strains, which makes it an attractive vaccine antigen for CF patients. A 
high molecular weight MEP vaccine elicited long-lived opsonic antibodies in 80–90% of the 
volunteers in phase I trial [142]. MEPs conjugated to various carrier proteins successfully 
enhanced the MEP-specific immune responses and elicited opsonizing antibodies against het-
erologous MEPs in mice and rabbits [143]. However, a successful clinical product has not yet 
been developed, indicating that vaccine of MEP alone may not be sufficient for potent immu-
nization in human and conjugation with other vaccine targets may be considered.
4.7. Inactivated whole-cell vaccine and antibody development against P. aeruginosa
Whole cell-inactivated vaccines contain multiple bacterial antigenic components and thus can 
potentially induce diverse immunologic responses against various targets of P. aeruginosa. 
Oral immunization of bronchiectasis patients with an enteric-coated whole-cell killed vac-
cine resulted in significant reduction of P. aeruginosa in the sputum by specific lymphocyte 
responses [144]. Oral immunization of healthy volunteers with killed Pseudomonas vaccine 
was safe and increased Pseudomonas-specific serum antibodies, most notably IgA, and pro-
moted phagocytosis elimination of P. aeruginosa [145]. Whole cell inactivation by X-ray irradi-
ation kept antigen expression functional but inhibited replication in P. aeruginosa [146]. Mice 
immunized with this vaccine showed statistically significant protection against P. aeruginosa 
challenge in acute pneumonia model via opsonic killing, recruitment of CD4+ T lymphocytes 
and neutrophil cells [146].
4.8. Antibody and vaccine development against exotoxin
Exotoxin A is a key virulence factor secreted by around 90% P. aeruginosa clinical isolates and 
around 10,000 times more lethal than LPS [147, 148]. Exotoxin A is an ADP-ribosyltransferase 
and can kill macrophages, polymorphonuclear leukocytes, and other immune-related cells by 
receptor-mediated endocytosis and inhibition of protein synthesis elongation factor 2 [148].
mAbs against two epitopes of exotoxin A after immunization of rabbits showed potent inhibi-
tion of exotoxin A-induced cytotoxic activity in vitro [149]. Furthermore, these mAbs showed 
protective effects against P. aeruginosa infection for mice after immunization and enhanced 
the survival rate of mice model when antibiotic amikacin was combined [150]. Similarly, 
immunization of mice with exotoxin A showed 93.8% protection efficacy against mice burn 
and P. aeruginosa-challenged models when compared with unimmunized mice group that all 
died within the 70-day period [151].
Chimeric vaccine composed of a nontoxic (active-site deletion) exotoxin A and a key pilin frag-
ment sequence was used to immune rabbits subcutaneously [152]. The produced antibodies could 
target against both pilin to weaken P. aeruginosa adherence and exotoxin A to neutralize its cyto-
toxic activity in vitro [152]. Intranasal immunization of chimeric vaccine (pilin and exotoxin A) in 
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mice elicited serum and saliva immune responses [153]. Moreover, saliva samples contain anti-
bodies that can inhibit pilin-dependent P. aeruginosa adherence and neutralize exotoxin A [153]. 
This approach of immunization may be useful to provide protection against P. aeruginosa early-
stage adhesion and infection via oropharyngeal airway [153].
5. Antibody development against A. baumannii
5.1. Iron-regulated outer membrane proteins (IROMP) as antibody and vaccine target
Iron is essential for bacteria to survive within host. Bacteria have evolved several ways to 
compete with host for iron uptake. Expression of iron-regulated outer membrane proteins 
(IROMPs) in bacteria is one such way. IROMPs, with molecular weight ranging from 77 to 
88 kDa, are a class of specific cell surface receptors that can bind iron chelator siderophore 
with high affinity and subsequently lead to the internalization of iron-loaded siderophore 
and iron assimilation in A. baumannii [154, 155]. Goel et al. [155] used IROMPs from A. bau-
mannii to immunize BALB/c mice and identified several mAbs of IgM isotype that can block 
interaction of siderophore with IROMPs and induce bactericidal and opsonizing activity 
in vitro.
5.2. Inactivated whole cell, outer membrane complexes (OMCs), and outer membrane 
vesicles (OMVs) as vaccine and antibody target
Immunization of mice with inactivated whole A. baumannii, prepared from formalin-treat-
ment, elicited protective antibody response against A. baumannii post-infection challenge in 
mice sepsis model [156]. Subsequently, these antibodies separated from immunized mice 
sera also showed passive protection against mice with A. baumannii infection [156]. As inac-
tivated whole A. baumannii vaccine contains LPS (endotoxin) that may complicate immune 
responses after immunization, LPS-deficient and inactivated whole A. baumannii cell was 
used to immune mice [157]. Similar humoral and cellular immune responses was observed as 
compared with wild-type inactivated whole A. baumannii vaccine in protection against differ-
ent mouse models with disseminated A. baumannii infections of various strains [157].
Vaccine made of outer membrane complexes (OMCs) from A. baumannii induced protective 
humoral and cellular immune responses against murine sepsis model [158]. Similarly, pas-
sive transfer of antiserum from immunized murine to naive mice rescued these mice from 
A. baumannii infection [158].
Outer membrane vesicles (OMVs), released from Gram-negative outer cell wall surface, have 
a diameter within the range of 50–250 nm and contain all constituents as Gram-negative 
outer cell wall, such as proteins, LPS, phospholipids, DNAs, and RNAs [159–161]. OMVs 
play important pathological roles by delivering virulence factors into host cell and coordinate 
group communications known as quorum sensing [160, 161]. High-dose challenging of mice 
with OMVs (200 μg) triggered a strong pro-inflammatory cytokine release that may be patho-
logical to host [162].
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Interestingly, immunization of mice with low dose OMVs (10 μg) from one clinical MDR A. bau-
mannii isolate induced clear protection against mice pneumonia and sepsis models after A. bau-
mannii challenge [163]. The protective mechanism is in part from specific anti-OMV antibody 
induced opsonophagocytic activity and suppressed pro-inflammatory cytokine release [163].
Recently, OMVs were engineered as a delivery vehicle to package and display Omp22 at the 
OMV surface [164]. The displayed Omp22-OMV can induce high-titer anti-Omp22 specific 
antibodies and protect mice from sepsis after lethal A. baumannii challenge [164].
5.3. Targeting outer membrane protein A (OmpA)
Outer membrane protein A (OmpA), previously known as Omp38, is a lethal and most abun-
dantly expressed surface virulence factor in A. baumannii [165, 166]. OmpA belongs to the 
porin family with low permeability that may be a key factor contributing to its multidrug 
resistance [167]. OmpA can bind with host cell directly, internalize within mitochondria and 
nuclei compartments of host cell, and induce host cell death [165, 166]. Moreover, OmpA is 
highly conserved within six clinical isolates (99% protein sequence identity) and 14 other 
NCBI GenBank deposited sequences from different isolates of A. baumannii (89% protein 
sequence identity), while OmpA shows no homology to human proteins [168].
Thus, OmpA from A. baumannii is a potentially ideal vaccine and antibody target.
In agreement with the sequence identity analysis, immunization of diabetic mice subcutaneously 
with recombinant OmpA induced markedly protective effect upon lethal, extreme drug resistant-
A. baumannii challenge; use of antibodies against OmpA also elicited similar protective effect 
on diabetic mice with lethal A. baumannii infection [168]. Interestingly, dosage of A. baumannii 
rOmpA vaccine correlates with various B cell epitopes and immunodominant T cell epitopes, 
emphasizing dosage needs to be taken into account for vaccine development [169]. Recently, 
intranasal immunization of mice with OmpA can trigger both mucosal and systemic protective 
antibodies against MDR A. baumannii infection [170].
Omp22 is an outer membrane protein with molecular weight of 22-kDa. Omp22 is more than 
95% conserved within 851 reported A. baumannii strains [171]. In contrast, there is no homol-
ogy with human proteins. This unique and conserved sequence makes Omp22 an ideal vac-
cine candidate. Immunization of mice with recombinant Omp22 induced clear protection 
from MDR A. baumannii infections, showing a potential vaccine candidate [171].
FilF is a highly conserved outer membrane protein predicted to be involved in pilus assem-
bly in A. baumannii [172]. Immunization of mouse pneumonia model induced high titer of 
antibody, decreased the bacteria lung burden, and rescued around 50% of mice from lethal 
A. baumannii infection [172]. These promising results may suggest that FilF is a promising vac-
cine candidate for further evaluation [172].
5.4. Biofilm related proteins as vaccine and antibody target
Biofilms are bacterial communities connected by a surface of extracellular matrix with 
complicated compositions that may vary based on different bacteria and different living 
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environments [173]. Identified biofilm components contain polysaccharides, proteins, and 
extracellular DNAs and play essential pathological roles in bacterial adhesion to host cell and 
shielding bacteria from nearby pressures such as antibiotics [173, 174].
Surface polysaccharide poly-beta-(1-6)-N-acetylglucosamine (PNAG), as a major component 
of biofilm, is a key virulence factor in A. baumannii [175]. Immunization of rabbit with conjuga-
tion of a synthetic oligosaccharide, mimicking PNAG, with tetanus toxoid induced antibodies 
that can opsonize clinical isolates of A. baumannii with surface expression of PNAG in vitro and 
protect A. baumannii challenged mice [176].
Biofilm-associated protein (Bap) in A. baumannii, 8620 amino acids in length, is one of the largest 
proteins identified within bacterial proteins and plays a vital role in biofilm formation [177]. Bap, 
containing seven tandem repeats of modules, is 41–66% conserved among clinical isolates and 
its expression is induced by low iron concentration [177, 178]. Immunization of mice with one 
region of Bap from A. baumannii elicited protective immunity against A. baumannii of different 
strains, suggesting that Bap is conserved and can be used as a potential vaccine candidate [179].
Ata, a trimeric transporter and a key virulence factor in A. baumannii, is essential in biofilm 
formation [180]. Rabbit sera from Ata vaccination can opsonize A. baumannii isolates effec-
tively in complement and polymorphonuclear cells dependent manners [181]. Moreover, the 
rabbit sera can significantly lower the burden of mice lung infection from MDR A. baumannii 
strains, showing that Ata is one more potential vaccine target [181].
5.5. Targeting K1 capsular polysaccharide
K1 capsular polysaccharides are an important virulence factor that helps A. baumannii to 
establish infections within host [182]. Immunization of mice with sub-lethal and K1 capsu-
lar polysaccharide positive A. baumannii induced generation of specific anti-K1 capsular 
polysaccharide IgM monoclonal antibody (13D6) [183]. Moreover, 13D6 can induce efficient 
neutrophil-mediated in vitro opsonization and in vivo passive protectivity in rat soft tissue 
infection model [183]. However, only 13% of 100 collected A. baumannii strains were positive 
against 13D6, suggesting other capsular polysaccharide serotypes that may be unexplored. 
Additionally, lack of immunoglobulin class switch from IgM to IgG may not effectively trigger 
adaptive long-term immune memory response. Failure of class switching may be the inher-
ent property of most capsular polysaccharides that only elicits a T cell independent immune 
response after immunization [184]. Thus, to target more A. baumannii strains effectively, identi-
fication of more capsular polysaccharide serotypes and conjugation of capsular polysaccharide 
with carrier proteins may be needed. As a matter of fact, this strategy has been successfully 
applied in clinics for the prevention of Streptococcus pneumoniae infection by the introduction 
of 23-valent nonconjugated and 13-valent conjugated capsular polysaccharide vaccines [185].
6. Concluding remarks
Antibody and vaccine are important treatment options in the mobilization of human immune 
system passively or actively to recognize, kill bacteria enemies, and moreover memorize these 
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enemies for the long-term protection. Antigen selection is the key for antibody and vaccine 
development, which needs to be immunogenic and conserved. Initially, antibody and vac-
cine development mainly focused on individual antigen. It is now clear that multivalent anti-
gens should be more potent in eliciting immune responses against bacteria. Combination of 
pan-genomics, proteomics, and reverse vaccinology analysis of bacteria revealed a list of con-
served antigens as potential vaccine or antibody targets and some of these antigens are already 
known as virulence factors of related bacteria [186, 187]. These bioinformatics-based “omics” 
analysis will undoubtedly facilitate effective vaccine and antibody target identification and 
development.
Other alternatives to antibiotics, including short antimicrobial peptides, antibiofilm peptides, 
and host defense peptides, are not covered in this chapter; readers can refer to a recent excel-
lent review and references therein for further information [188].
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